Nadia Harbeck

75PUBLICATIONS
423CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersModels of care and place of birthCancer diagnosisCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (75)

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Nov 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Oct 08, 2025
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.

Shanu Modi, William Jacot, Hiroji Iwata

|Aug 27, 2025
Attitudes toward AI-generated risk prediction in patients with early breast cancer: an international multicenter survey.

Frederik Voigt Carstensen, Sofie A M Gernaat, Friederike Banning

Pageof 13

Frequent Collaborators

9 joint publications

Sherko Kümmel

8 joint publications

Seock-Ah Im

8 joint publications

Miguel Martin

7 joint publications

Javier Cortés